← Leaderboards
Jacques Turgeon
Hesperos, Llc
$1,733,681
Attributed
$3,467,361
Total exposure
1
Grants
0
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $1.5M · FY2021–25$2M$1.5M$1M$500K$0
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$3,467,361 · 1
By mechanism
R44$3,467,361 · 1
Top collaborators
- James J Hickman4 shared
Others in their field
Other Emerging Leaders on “Alzheimer&Apos”
- Lance Allen Johnson · University Of Kentucky$7,508,882
- Hyacinth Idu Hyacinth · University Of Cincinnati$6,781,590
- Yi Su · Weill Medical Coll Of Cornell Univ$6,486,733
- Julia Tcw · Icahn School Of Medicine At Mount Sinai$6,079,215
- Jessica Brooke Langbaum · Banner Health$6,050,741
- Timothy Yikai Huang · Sanford Burnham Prebys Medical Discovery Institute$5,936,362
Research focus
Alzheimer&AposFrail ElderlyAlgorithmsDrug InteractionsCollaborationsElderlyComorbidityCellsDementiaDoseAnti-CholinergicsAdverse Event RiskCognitiveDrug UsageCytochrome P450Adverse Drug EventDrug MetabolismBlood - Brain Barrier AnatomyAdverse EventBurden Of IllnessDementia RiskCaringCause Of DeathHigh Risk
Grant awards (4)
Modulatory Role of Blood-Brain-Barrier and Enzymatic Activity in an Innovative Human Model of Anticholinergic Drug Induced Dementia$1,500,000
R44 · FY2025 · AG
Modulatory Role of Blood-Brain-Barrier and Enzymatic Activity in an Innovative Human Model of Cholinergic Drug Induced Dementia$902,299
R44 · FY2022 · AG
Hesperos Diversity Supplement forgrant number 1 R44AG071386$162,742
R44 · FY2022 · AG
Modulatory Role of Blood-Brain-Barrier and Enzymatic Activity in an Innovative Human Model of Cholinergic Drug Induced Dementia$902,320
R44 · FY2021 · AG